Feb 10, 2026 | Benefits Advisory Conference, Benefits management, Cancer, Caroline Fraker, Compliance, Forensic claims review, Gene therapy, GLP-1s, High-cost claims, MedBen University, No Surprises Act (NSA), Obesity, Orphan diseases, Pharmacy, Specialty Drugs, Stop-Loss, Transplants
Consultants and advisors from 10 different states attended the MedBen 2026 Benefits Advisory Conference on January 28. The event featured insights from some of the industry’s most respected voices and gave brokers a clearer view of today’s benefits landscape, what...
Dec 15, 2025 | GLP-1s, MedBen Rx, Medicaid, Pharmacy, Private employers, Weight loss, Weight loss drugs
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
Sep 5, 2025 | Diabetes, GLP-1s, Weight loss drugs, Wellness
A recent Forbes article highlights ongoing concerns about GLP-1 weight-loss drugs: “Large-scale studies show that GLP-1s don’t lead to medical cost savings, at least not in the short term… healthcare expenditures rose, with inpatient costs accounting for the...
Jul 1, 2025 | Cost Savings, Drug costs, GLP-1s, MedBen Rx, Ozempic, Rebates, Rx Costs, Specialty Drugs, Wegovy, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
May 19, 2025 | Biosimilars, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
